(Bloomberg) — Wedbush Securities, the Los Angeles-based brokerage consistently ranked among the top firms by Nasdaq trading volume, was accused by the U.S. Securities and Exchange Commission of ...
Dan Ives, Wedbush global head of technology research, joins 'Closing Bell: Overtime' to discuss Salesforce after the ...
The videogame retailer’s shares jumped following the latest cryptic post from influential trader Keith Gill, aka “Roaring ...
What makes that call particularly surprising is that most pundits are still skeptical about Palantir. Among the 20 analysts ...
Wedbush raised their Q1 2025 earnings estimates for Keros Therapeutics in a report released on Tuesday, December 3rd. Wedbush ...
Musk reacted on his X social media platform to the ruling on Monday by Court of Chancery Judge Kathleen McCormick.
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...
Wedbush analyst Daniel Ives raised the firm’s price target on Palantir to $75 from $57 and keeps an Outperform rating on the shares. It is time ...
Shares of Palantir Technologies (PLTR, Financial) rallied 1.5% to $65 on Monday after Wedbush Securities raised its price target from $57 to $75, reiterating an outperform recommendation. This move ...
Additionally, one closely watched Wall Street analyst said that AI software stocks would be winners in 2025. As a result, ...
VinFast Auto Ltd. (NASDAQ:VFS – Free Report) – Equities researchers at Wedbush raised their FY2024 EPS estimates for shares of VinFast Auto in a research note issued on Wednesday, November 27th.
Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s TRACER platform. The investment firm said it believes TRACER alone should ...